Korlym® provided improvements in symptoms of hypercortisolism
In addition, mean total fat mass decreased by 13.9% (P<.001).4
Reduction of 8.4 ± 5.9 cm for men (P<.001)1
Reduction of 6.8 ± 5.8 cm for women (P<.001)1
†Because of the variability in clinical presentation and variability of response in this open-label study, it is uncertain whether these changes could be ascribed to the effects of Korlym.
C-DM, patients with CS and T2DM/IGT; IGT, impaired glucose tolerance; oGTT, oral Glucose Tolerance Test; T2DM, type 2 diabetes mellitus.
*Study design: SEISMIC (Study of the Efficacy and Safety of Mifepristone in the Treatment of Endogenous Cushing’s Syndrome) was a phase 3, uncontrolled, open-label, 24-week, multicenter clinical study of 50 subjects with endogenous Cushing syndrome. All 50 subjects had clinically significant hypercortisolism. Subjects received 300 mg to 1200 mg of Korlym per day for up to 24 weeks. Forty-three patients had Cushing disease, of which 42 had previously undergone pituitary surgery. Four patients had ectopic adrenocorticotropic hormone (ACTH) secretion, and 3 had adrenal carcinoma. Forty-six subjects received at least 30 days of dosing during the 24-week study period and were included in a modified intent-to-treat analysis.
Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and
glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the
termination of pregnancy. Pregnancy must therefore be excluded before the initiation of
treatment with Korlym and prevented during treatment and for one month after stopping
treatment by the use of a nonhormonal medically acceptable method of contraception unless
the patient has had a surgical sterilization, in which case no additional contraception is needed.
Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females
of reproductive potential.
Obtain a negative pregnancy test prior to initiating treatment with Korlym in females of
reproductive potential, or if treatment is interrupted for more than 14 days.
Administer once daily orally with a meal. The recommended starting dose is 300 mg once daily.
Renal impairment: Do not exceed 600 mg once daily. Mild-to-moderate hepatic impairment: Do
not exceed 600 mg once daily. Do not use in severe hepatic impairment. Based on clinical
response and tolerability, the dose may be increased in 300-mg increments to a maximum of
1200 mg once daily. Do not exceed 20 mg/kg per day.
Concomitant use of Korlym with a strong CYP3A inhibitor resulted in a 38% increase in mean
plasma concentration of mifepristone. For patients already being treated with a strong CYP3A
inhibitor, start with a Korlym dose of 300 mg per day and titrate to a maximum of 900 mg per
day if clinically indicated. When a strong CYP3A inhibitor is administered to patients already
receiving Korlym, adjust the dose as follows: for patients receiving a daily dose of 600 mg,
reduce dose to 300 mg. For patients receiving a daily dose of 900 mg, reduce dose to 600 mg.
For patients receiving a daily dose of 1200 mg, reduce dose to 900 mg. Titrate if clinically
indicated and do not exceed a Korlym dose of 900 mg in combination with a strong CYP3A
Pregnancy; patients taking simvastatin or lovastatin and CYP3A substrates with narrow
therapeutic ranges; patients receiving systemic corticosteroids for lifesaving purposes; women
with a history of unexplained vaginal bleeding or endometrial hyperplasia with atypia or
endometrial carcinoma; patients with known hypersensitivity to mifepristone or to any of the
Adrenal insufficiency: Patients should be closely monitored for signs and symptoms of adrenal
Hypokalemia: Hypokalemia should be corrected prior to treatment and monitored for during
Vaginal bleeding and endometrial changes: Women may experience endometrial thickening or
unexpected vaginal bleeding. Use with caution if the patient also has a hemorrhagic disorder or is
on anticoagulant therapy.
QT interval prolongation: Avoid use with QT interval-prolonging drugs, or in patients with
potassium channel variants resulting in a long QT interval.
Use of strong CYP3A inhibitors: Concomitant use increases mifepristone plasma levels. Adjust
Korlym dose as described in Dosage and Administration. Use only when necessary and do not
exceed a Korlym dose of 900 mg.
Most common adverse reactions in Cushing’s syndrome (≥20%): nausea, fatigue, headache,
decreased blood potassium, arthralgia, vomiting, peripheral edema, hypertension, dizziness,
decreased appetite, endometrial hypertrophy.
Drugs metabolized by CYP3A: Administer drugs that are metabolized by CYP3A at the lowest
dose when used with Korlym.
CYP3A inhibitors: Caution should be used when Korlym is used with strong CYP3A inhibitors.
Adjust Korlym dose as described in Dosage and Administration. Use only when necessary, and
do not exceed a Korlym dose of 900 mg.
CYP3A inducers: Do not use Korlym with CYP3A inducers.
Drugs metabolized by CYP2C8/2C9: Use the lowest dose of CYP2C8/2C9 substrates when used
Drugs metabolized by CYP2B6: Use of Korlym should be done with caution with bupropion and
Hormonal contraceptives: Do not use with Korlym.
Lactation: Mifepristone is present in human milk, however, there are no data on the amount of
mifepristone in human milk, the effects on the breastfed infant, or the effects on milk production
during long term use of mifepristone.
Please see accompanying full Prescribing Information and Medication Guide.
Korlym® (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia
secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have
type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for
Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing’s